It is believed that p-MET is a promising therapeutic target due to its elevated expression in multiple TNBC subtypes, which indicates that, by inhibiting the HGF/MET signaling pathway, foretinib may exert an antitumor effect through a direct cytotoxic effect on tumor cell proliferation [14,15]. The gene discussed is MET; the disease is neoplasm.